Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (3231)	12/8/1997 4:33:00 PM
From: PAL	Read Replies (3) \| Respond to of 6136

Had a chance to watch Peter Johnson on Squawk Box/CNBC this morning. I get the impression that, this guy who is a brilliant researcher in biotech is not a public speaker. His answers were dull and did not exploit the opportunity to present his case. Like when Joe Kernen gave him a lead by asking him that should not APGH be rewarded - instead of a drastic devaluation ot its stock - by cutting its losses on Thymataq which would generate only $ 25M compared to $ 350M of Viracept, Johnson's answer was: AGPH is researching further into a better combination of drugs to be taken together with Viracept. He did not reply to the question about future competition. I did expect that Johnson will come out swinging saying Viracept will be around for at least a decade (or decades). Needless to say, the his appearance by very brief. Maybe Mark Haines cut it short because Johnson is not interesting. That interview strengthens my dream that Merck should takeover AGPH, let Peter Johnson do research, the public relation duties be handled by a professional. Merck needs Agouron and vice versa ... badly. Paul.